Daniel Feig, MD, PhD, MS
Dr. Feig's research interest is in understanding the early physiology of essential hypertension. He directs laboratory, clinical physiology, and clinical trial projects directed at elucidating the early steps from high normal blood pressure to overt hypertension with the goal of developing strategies for the primary prevention of essential hypertension.
One of Dr. Feig's long-standing interests is in the role of elevated uric acid in inducing hypertension through damage to the afferent arteriole of the kidney, renal parenchymal inflammation and endothelial dysfunction. These three pathways are central to the initiation and maintenance of hypertension. Animal model data indicate that elevated uric acid causes increased blood pressure through a reversible vasoconstrictive mechanism but over time leads to renovascular alterations that cause an irreversible salt sensitive hypertension. Children with early onset essential hypertension appear to follow a similar pattern and preliminary results suggest medications that lower uric acid ameliorate this process. Current projects are directed at the further elucidation of uric acid mediated vasoconstriction and arteriolosclerosis in human systems and attenuation of early hypertensive changes in obese adolescents.
Dr. Feig is actively involved in projects designed to improve therapy for hypertension in children, including several multi-center pharmaceutical trials as well as the design of optimal dietary and exercise therapy for the management of obesity related hypertension.
David Askenazi, MD, MsPH
Dr. Askenazi is dedicated to improving outcomes in neonates at risk for AKI. Recently in a prospective 18 month study at UAB, he has shown that AKI is common and is independently associated with mortality. His team has also shown that urine biomarkers can predict AKI and mortality in premature infants. He is currently working to study the epidemiology and urine biomarkers of AKI in term newborns and is exploring the role of heme-oxygenase-1 in neonatal AKI. Other current interests include: a protocol to reduce fluid overload and length of ventilator support in children undergoing cardiopulmonary bypass, epidemiology of AKI in children after bone marrow transplant, and prevention of AKI in hospitalized children with cystic fibrosis.
Sahar Fathallah-Shaykh, MD
Dr. Fathallah is interested in chronic kidney disease and dialysis in children. She has studied changes in blood viscosity in dialysis patients. She is currently the Medical Director of the dialysis unit at Children's of Alabama. She is the center principal investigator for the Chronic Kidney Disease in Children (CKiD) study, the largest NIH-funded North American multi-center study of pediatric chronic kidney disease. She is involved in multi-center pharmaceutical trials on the pharmacokinetic and pharmacodynamics of medications used in patients on dialysis or with chronic kidney disease.
Michael Seifert, MD, MSCI
Dr. Seifert is interested in the role of endothelial health and dysfunction in chronic allograft injury and fibrosis; biomarkers associated with cardio-renal disease in native and transplant CKD; early determinants of long-term outcomes in pediatric kidney transplantation.